I Peace Recognized with Longevity Breakthrough Award
Biotechnology firm I Peace Inc. has received recognition for its pioneering work in cell technologies aimed at promoting longevity. The award was presented for the company's development of its cell-free product, iPSF.
Palo Alto, Calif. – Biotechnology company I Peace Inc. has been selected as one of ten awardees for the Top 10 Longevity Breakthrough Awards at the 2026 Asia-Pacific Healthy Longevity International Summit. The company was recognized for its research and development of iPSF, a cell-free product derived from the culture supernatant of induced pluripotent stem cells (iPS cells).
Dr. Koji Tanabe, Founder and CEO of I Peace, Inc., expressed honor for the recognition, stating it reflects the team's dedication to advancing iPS cell technology and exploring new longevity approaches. The Longevity Breakthrough Awards aim to acknowledge innovative technologies and research with the potential to contribute to healthy longevity, based on scientific and medical evidence.
I Peace has focused on developing a cell-free technology that utilizes bioactive factors produced by iPS cells, rather than administering the cells themselves. Research into iPSF has observed potential effects on extracellular matrix production and age-associated biomarkers. The company is currently investigating the mechanisms of action, safety, and potential utility of iPSF for various tissues whose function may decline with age, including skin and hair.
Longevity medicine research has expanded rapidly globally. I Peace operates across three key pillars: manufacturing clinical and research-grade iPS cells through its GMPeace service, personal iPS cell banking via the My Peace service, and longevity-focused research and development based on iPS cell technology. The company plans to carefully assess reproducibility, safety, and clinical relevance through appropriately designed studies.